Bullous pemphigoid is an autoimmune skin disease where the immune system attacks skin adhesion proteins
In short: Your immune system normally protects you, but in bullous pemphigoid it turns on the skin itself. Antibodies target proteins that hold the outer layers together, producing tense, fluid-filled blisters. Mostly seen in people over 60, it can fade on its own over months or years, yet its early symptoms often mimic eczema or hives, which makes it easy to miss.
Bullous pemphigoid is an itchy, autoimmune skin condition that mainly affects people over 60. Doctors place it among type II hypersensitivity reactions, meaning the body's own antibodies cause the damage. In this disease, IgG autoantibodies target two proteins, dystonin and type XVII collagen, which form part of hemidesmosomes. These structures help anchor the top layer of skin to the layer beneath it. Once the antibodies bind, immune cells such as neutrophils, lymphocytes and eosinophils gather in the affected area, and the skin separates at the junction between its layers, forming blisters. The disease usually unfolds in two phases. The first is a non-bullous phase, which can last weeks to months and brings intense itching with eczema-like or hives-like lesions. The second is the bullous phase, in which tense blisters filled with clear fluid appear, most often on the abdomen, limbs and lower trunk, typically between 1 cm and 4 cm across. Blisters commonly erupt on the inner thighs and upper arms, while mouth sores occur in only a minority of cases. Because these early features resemble other conditions, diagnosis relies on a 2-out-of-3 rule that combines symptoms, direct immunofluorescence on a skin biopsy and indirect immunofluorescence on a blood serum sample.
Treatment depends on severity. Topical steroids such as clobetasol have been found in some studies to work about as well as steroid pills while carrying less risk. Harder cases may need prednisone or steroid-sparing immunosuppressants such as methotrexate, azathioprine or mycophenolate mofetil, which can harm the kidneys and liver or raise infection risk. Antibiotics like tetracycline or erythromycin can help people who cannot take corticosteroids, and the anti-CD20 antibody rituximab helps some otherwise hard-to-treat cases. A 2010 review of 14 randomised trials, updated in 2023, found oral and potent topical steroids effective, while lower topical doses were judged safe and effective for moderate disease. The condition is very rare in children. Estimates place its frequency at about seven to 14 cases per million people per year, though one group, men over 85 in Scotland, has been reported at a much higher rate. Sex differences are disputed, with some sources finding men affected more often and others finding no gap. The disease can resolve by itself, and poorer general health in old age is linked to a weaker outlook. Mouse models lacking the two known target proteins are helping researchers study it further.
Bullous pemphigoid is a useful example of how autoimmunity can target a body's own structural proteins.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Bullous pemphigoid
- Also: Cureus — Recurrent Bullous Pemphigoid: A Case Report. · CC BY
To cite this card, link to https://intellectplus.co.uk/app/health-bullous-pemphigoid.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health, medicine and disease · More in Health · Latest · A–Z · All topics